Search results for "Fumarate"

showing 10 items of 97 documents

Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?

2011

Objective: Baseline inhaled corticosteroid (ICS) dose may be a factor for prescribers to consider when they select a budesonide/formoterol maintenance and reliever therapy regimen for symptomatic asthmatics. Methods: A 6-month randomized study compared two maintenance doses of budesonide/formoterol 160/4.5 µg, 1 × 2 and 2 × 2, plus as needed, in 8424 asthma patients with symptoms when treated with ICS ± an inhaled long-acting β2-agonist (LABA). In the total study population, 1339 (17%) were high-dose ICS (HD) users (≥1600 µg/day budesonide). This HD stratum was compared with the rest of the study population, divided into low-dose (LD; 400 µg/day) and medium-dose strata (MD; 401–1599 µg/day…

Pulmonary and Respiratory MedicineBudesonideAdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classSeverity of Illness Indexlaw.inventionYoung AdultRandomized controlled triallawAdrenal Cortex HormonesInternal medicineSurveys and QuestionnairesAdministration InhalationmedicineBudesonide Formoterol Fumarate Drug CombinationHumansPharmacology (medical)Anti-Asthmatic AgentsBudesonideAsthmaAgedlcsh:RC705-779Aged 80 and overDose-Response Relationship Drugbusiness.industrylcsh:Diseases of the respiratory systemMiddle Agedmedicine.diseaseAsthmaRegimenDrug CombinationsTreatment OutcomeBudesonide/formoterolAsthma Control QuestionnaireEthanolaminesAnesthesiaCorticosteroidFemaleFormoterolbusinessmedicine.drugTherapeutic advances in respiratory disease
researchProduct

The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever u…

2012

Abstract Background Divergent strategies have emerged for the management of severe asthma. One strategy utilises high and fixed doses of maintenance treatment, usually inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), supplemented by a short-acting β2-agonist (SABA) as needed. Alternatively, budesonide/formoterol is used as both maintenance and reliever therapy. The latter is superior to fixed-dose treatment in reducing severe exacerbations while achieving similar or better asthma control in other regards. Exacerbations may be reduced by the use of budesonide/formoterol as reliever medication during periods of unstable asthma. We examined the risk of a severe exacerbation in the per…

Pulmonary and Respiratory MedicineBudesonideExacerbationAsthma in primary careSeverity of Illness Indexlaw.inventionRandomized controlled trialDouble-Blind MethodlawAdrenal Cortex HormonesRisk FactorsFormoterol FumarateAdministration InhalationmedicineBudesonide Formoterol Fumarate Drug CombinationHumansAnti-Asthmatic AgentsBudesonideAsthmalcsh:RC705-779Maintenance dosebusiness.industryResearchlcsh:Diseases of the respiratory systemmedicine.diseaseAsthmaBronchodilator AgentsDrug CombinationsTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionFormoterol FumarateDrug Therapy CombinationFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugRespiratory research
researchProduct

Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution

2022

Although bronchodilators are the cornerstone in chronic obstructive pulmonary disease (COPD) therapy, the treatment with a single-agent bronchodilator may not provide adequate symptoms control in COPD. The combination of drugs with different mechanisms of action may be more effective in inducing bronchodilation and preventing exacerbations, with a lower risk of side-effects in comparison with the increase of the dose of a single molecule. Several studies comparing the triple therapy with the association of long-acting ß2 agonist (LABA)/inhaled corticosteroid (ICS) or long-acting muscarinic antagonist (LAMA)/LABA reported improvement of lung function and quality of life. A significant reduc…

Pulmonary and Respiratory MedicineRC705-779ReviewMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioCOPD inhaled extrafine formulation triple therapyinhaled extrafine formulationBronchodilator AgentsDrug CombinationsPulmonary Disease Chronic ObstructiveDiseases of the respiratory systemtriple therapyFormoterol FumarateAdministration InhalationQuality of LifeCOPDHumansDrug Therapy CombinationPharmacology (medical)Adrenergic beta-2 Receptor AgonistsTherapeutic Advances in Respiratory Disease
researchProduct

Escherichia coli possesses two homologous anaerobic C4-dicarboxylate membrane transporters (DcuA and DcuB) distinct from the aerobic dicarboxylate tr…

1994

The nucleotide sequences of two Escherichia coli genes, dcuA and dcuB (formerly designated genA and genF), have been shown to encode highly homologous products, M(r) 45,751 and 47,935 (434 and 446 amino acid residues) with 36% sequence identity (63% similarity). These proteins have a high proportion (approximately 61%) of hydrophobic residues and are probably members of a new group of integral inner membrane proteins. The locations of the dcu genes, one upstream of the aspartase gene (dcuA-aspA) and the other downstream of the anaerobic fumarase gene (fumB-dcuB), suggested that they may function in the anaerobic transport of C4-dicarboxylic acids. Growth tests and transport studies with mut…

Sequence analysisMolecular Sequence DataMutantSuccinic AcidBiologymedicine.disease_causeMicrobiologyProtein Structure SecondarySubstrate SpecificityProtein structureBacterial ProteinsFumaratesEscherichia colimedicineAmino Acid SequenceAnaerobiosisMolecular BiologyGeneEscherichia coliPeptide sequenceDicarboxylic Acid Transporterschemistry.chemical_classificationAspartic AcidBase SequenceSequence Homology Amino AcidEscherichia coli ProteinsMembrane ProteinsBiological TransportSuccinatesSequence Analysis DNAAerobiosisAmino acidRepressor ProteinschemistryBiochemistryMembrane proteinGenes BacterialCarrier ProteinsResearch ArticleTranscription FactorsJournal of Bacteriology
researchProduct

CCDC 769594: Experimental Crystal Structure Determination

2010

Related Article: L.Orola, M.V.Veidis|2010|Acta Crystallogr.,Sect.E:Struct.Rep.Online|66|o1597|doi:10.1107/S1600536810017708

Space GroupCrystallographybis(NN'-diphenylbenzamidinium) fumarateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Determination of aerobic-anaerobic metabolism-related compounds in aChaoborus flavicans population by infusion ion trap mass spectrometry of extracts…

2006

In a daily migration, the aquatic larvae of Chaoborus flavicans (a phantom midge) alternate oxygen-saturated and anoxic lake strata. To investigate this cycle, larvae were collected at a natural environment, and acetate, propionate, pyruvate, lactate, glycerol, phosphate, maleate, succinate, glucose and citrate were determined. Each larva was homogenized with 200 microL water and deproteinized with a spin-filter; 50 microL aliquots were mixed with 50 microL of a buffer containing 80 mM propylamine, 20 mM HCl and 0.06 mM 2,4-dihydroxybenzoic acid (internal standard) in methanol. The extracts were infused in an electrospray ionization ion-trap mass spectrometer. The limits of detection for th…

Spectrometry Mass Electrospray IonizationElectrospray ionizationPopulationCeratopogonidaeMass spectrometryModels BiologicalAnalytical Chemistrychemistry.chemical_compoundFumaratesChaoborus flavicansGlycerolAnimalsAnaerobiosiseducationSpectroscopychemistry.chemical_classificationeducation.field_of_studyChromatographyOrganic ChemistryDiscriminant AnalysisMetabolismAerobiosischemistryLarvaPropionateAmmonium acetateRapid Communications in Mass Spectrometry
researchProduct

Function of DcuS from Escherichia coli as a Fumarate-stimulated Histidine Protein Kinase in Vitro

2002

The two-component regulatory system DcuSR of Escherichia coli controls the expression of genes of C(4)-dicarboxylate metabolism in response to extracellular C(4)- dicarboxylates such as fumarate or succinate. DcuS is a membrane-integral sensor kinase, and the sensory and kinase domains are located on opposite sides of the cytoplasmic membrane. The intact DcuS protein (His(6)-DcuS) was overproduced and isolated in detergent containing buffer. His(6)-DcuS was reconstituted into liposomes made from E. coli phospholipids. Reconstituted His(6)-DcuS catalyzed, in contrast to the detergent-solubilized sensor, autophosphorylation by [gamma-(33)P]ATP with an approximate K(D) of 0.16 mm for ATP. Up t…

Time FactorsHistidine KinaseProteolipidsDetergentsBiologymedicine.disease_causeModels BiologicalBiochemistryAdenosine TriphosphateFumaratesEscherichia colimedicinePhosphorylationPromoter Regions GeneticProtein kinase AMolecular BiologyEscherichia coliDose-Response Relationship DrugKinaseEscherichia coli ProteinsCell MembraneAutophosphorylationDNACell BiologyTransmembrane proteinDNA-Binding ProteinsKineticsResponse regulatorBiochemistryLiposomesPhosphorylationSignal transductionProtein KinasesProtein BindingSignal TransductionTranscription FactorsJournal of Biological Chemistry
researchProduct

Real-Time Nuclear Magnetic Resonance Detection of Fumarase Activity Using Parahydrogen-Hyperpolarized [1- 13 C]Fumarate

2019

Hyperpolarized fumarate can be used as a probe of real-time metabolism in vivo, using carbon-13 magnetic resonance imaging. Dissolution dynamic nuclear polarization is commonly used to produce hyperpolarized fumarate, but a cheaper and faster alternative is to produce hyperpolarized fumarate via PHIP (parahydrogen-induced polarization). In this work, we trans-hydrogenate [1-13C]acetylene dicarboxylate with para-enriched hydrogen using a commercially available Ru catalyst in water to produce hyperpolarized [1-13C]fumarate. We show that fumarate is produced in 89% yield, with succinate as a side product in 11% yield. The proton polarization is converted into 13C magnetization using a constant…

Time FactorsHydrogenNuclear Magnetic Resonancechemistry.chemical_element010402 general chemistrySpin isomers of hydrogenPhotochemistry01 natural sciencesBiochemistryCatalysisFumarate HydrataseCatalysisMagnetizationchemistry.chemical_compoundColloid and Surface ChemistryFumaratesMoleculeCarbon IsotopesMolecular StructureFumarase activityCarbon Isotopes; Fumarate Hydratase; Fumarates; Molecular Structure; Time Factors; Nuclear Magnetic Resonance BiomolecularGeneral Chemistry0104 chemical sciencesAcetylenechemistryFumaraseBiomolecularJournal of the American Chemical Society
researchProduct

Beclomethasone dipropionate and formoterol reduce oxidative/nitrosative stress generated by cigarette smoke extracts and IL-17A in human bronchial ep…

2013

Interleukin-17A (IL-17A), cigarette smoke and oxidative/nitrosative stress are involved in inflammatory airway diseases, and the mechanisms behind these processes are still poorly understood. We investigated whether recombinant human IL-17A (rhIL-17A), in combination with cigarette smoke extracts (CSE), increases the levels of inducibile nitric oxide synthase (iNOS), reactive oxygen species, nitrotyrosine (NT) and the activation of signal transducer and activator of transcription 1 (STAT-1) in normal human bronchial epithelial cells (16HBE). The effect of beclomethasone dipropionate (BDP), formoterol and their combination was also evaluated. We demonstrated that rhIL-17A or CSE alone increa…

Transcription GeneticNitric Oxide Synthase Type IIBronchiOxidative phosphorylationPharmacologyGene Expression Regulation EnzymologicCell Linechemistry.chemical_compoundFormoterol FumarateSmokeNitrilesmedicineButadienesGene silencingHumansGene SilencingPromoter Regions GeneticPharmacologychemistry.chemical_classificationReactive oxygen speciesbiologyNitrotyrosineInterleukin-17BeclomethasoneEpithelial CellsTobacco ProductsReactive Nitrogen SpeciesNitric oxide synthaseOxidative StressSTAT1 Transcription FactorchemistryEthanolaminesImmunologySTAT proteinbiology.proteinPhosphorylationFormoterolBiomarkersmedicine.drugEuropean journal of pharmacology
researchProduct

Generation of a proton potential by succinate dehydrogenase of Bacillus subtilis functioning as a fumarate reductase

2001

The membrane fraction of Bacillus subtilis catalyzes the reduction of fumarate to succinate by NADH. The activity is inhibited by low concentrations of 2-(heptyl)-4-hydroxyquinoline-N-oxide (HOQNO), an inhibitor of succinate: quinone reductase. In sdh or aro mutant strains, which lack succinate dehydrogenase or menaquinone, respectively, the activity of fumarate reduction by NADH was missing. In resting cells fumarate reduction required glycerol or glucose as the electron donor, which presumably supply NADH for fumarate reduction. Thus in the bacteria, fumarate reduction by NADH is catalyzed by an electron transport chain consisting of NADH dehydrogenase (NADH:menaquinone reductase), menaqu…

biologyATP synthaseBiochemistryChemistryProtonophoreSuccinate dehydrogenaseNADH dehydrogenasebiology.proteinReductaseFumarate reductaseBiochemistryRedoxElectron transport chainEuropean Journal of Biochemistry
researchProduct